Aprogenex Inc. announced Thursday that the underwriters ofits initial public offering have exercised their option topurchase an additional 85,000 shares of common stock(ASE:APG), resulting in additional net proceeds to the Houstoncompany of $671,000.
The IPO, which closed Oct. 15, was managed by H.J. Meyers &Co. Inc. and sold 1.25 million shares at $8.75 per share.
Aprogenex, which is developing DNA probe-based diagnostics,now has 4.5 million shares outstanding.
The stock lost 13 cents on Friday, closing at $7.88 a share.
(c) 1997 American Health Consultants. All rights reserved.